3 Best Small-Cap SMR & Nuclear Tech Stocks — Q2 2026
The small-cap Small Modular Reactor universe is almost empty — the big names graduated. Here are the 3 real small-caps left that fit a nuclear-tech thesis, plus why Oklo and NuScale are no longer on the list.
The small-cap Small Modular Reactor (SMR) universe has a visibility problem: the companies retail investors think of — Oklo, NuScale, BWX Technologies, Centrus — have all outgrown the small-cap range. Their market caps sit between $5B and $15B now, with Oklo alone above $14B after a 10x run since 2024. What's left below $2B is a much thinner bench: one HALEU enrichment play, one pre-revenue micro-reactor company, and one long-duration fuel-tech bet.
We scored every small-cap stock in our universe with nuclear-adjacent revenue or product exposure. These are the 3 names that fit a Q2 2026 nuclear-tech thesis while still meeting our small-cap definition.
Why Small-Cap Nuclear Is Different
Four structural realities shape the investable opportunity here:
- Capital intensity mismatch — Nuclear projects cost billions and take a decade. Small-caps can't build reactors. They can, however, sell into the supply chain that enables them
- Regulatory gatekeeping — NRC design certification takes 3-5 years. Most pre-revenue small-cap reactor companies are still in the pre-application phase; cash runway has to survive the review, not just reach it
- Fuel supply chain is the actual bottleneck — Advanced reactors need HALEU (19.75% enriched uranium); the US has no commercial-scale HALEU supply. This is where the investable economics live for small-caps, not in the reactor designs themselves
- Catalyst density is lumpy — A DOE contract, an NRC milestone, or a customer LOI can move these stocks 30-50% in a day. Position sizing matters more than in most sectors
Our scoring rewards cash runway, dilution discipline, and balance-sheet quality — which for pre-revenue nuclear names is almost all that matters. Revenue growth on a near-zero base is not a meaningful signal; a 12-month runway runway versus 36 months is.
Top 3 Small-Cap Nuclear Tech Stocks by Fundamental Score — Q2 2026
Get picks like these first.
Free weekly digest — top movers, score changes, new small-cap opportunities. No spam, unsubscribe anytime.
1. ASP Isotopes (ASPI) — Score: 68.8 | Grade: SOLID
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | +857% | 100 |
| Gross Margin | 38.6% | 58 |
| Cash Runway | 44 months | 100 |
| Debt/Equity | Net cash | 100 |
| P/S Ratio | 15.8x | 18 |
| Rule of 40 | >800 | 100 |
| Insider Ownership | 8.4% | 47 |
| 12m Dilution | +30.0% | 0 |
What drives the score: ASP Isotopes uses a proprietary Aerodynamic Separation Process to enrich isotopes at lower capital cost than traditional gas centrifuges. Two product lines matter: medical isotopes (Carbon-14, Silicon-28, Molybdenum-100) generating current revenue, and HALEU enrichment — the Achilles heel of the entire advanced-nuclear buildout. ASP's Pretoria facility came online in 2024/25 and is ramping commercial production; HALEU capacity at Iceland is the expansion bet. 44 months of runway on a net-cash balance sheet makes this the least fragile pre-commercial nuclear story in the small-cap universe.
Key risk: Three specific things could break this thesis. First, technology scale-up: ASP's enrichment method has never operated at full commercial HALEU scale — it works in pilot, but Centrus has the only US-based cascade that's actually made HALEU at commercial spec. Second, the 30% dilution over 12 months: management is funding the build-out through equity issuance, and the pace will probably continue through 2027. Third, the 15.8x P/S ratio already prices in commercial HALEU success — if DOE HALEU Availability Program contracts go to Centrus instead, the valuation unwinds.
2. Nano Nuclear Energy (NNE) — Score: 43.1 | Grade: SPECULATIVE
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | 0% | 0 |
| Gross Margin | N/A | 0 |
| Cash Runway | >36 months | 100 |
| Debt/Equity | Net cash | 100 |
| P/S Ratio | N/A (no revenue) | 50 |
| Rule of 40 | N/A | 0 |
| Insider Ownership | 22.1% | 91 |
| 12m Dilution | +18.0% | 12 |
What drives the score: Nano Nuclear is a pure-play designer of portable micro-reactors — Zeus (solid-core), Odin (molten-salt), and Kronos. Unlike Oklo's Aurora design (which has been through NRC pre-application review), NNE's designs are still in conceptual-through-early-engineering stage; the company hasn't filed for NRC design certification yet. What makes this work as a small-cap thesis at all is the $1.29B market cap being supported by genuinely deep pockets: 125 months of runway at current burn, minimal debt, and an unusually high 22% insider ownership for a post-IPO name. Management is funding R&D, not operations — so every quarter of runway is a real option on reaching a demonstration reactor.
Key risk: The specific risk: NNE is Oklo's market, 3-4 years behind. If Oklo delivers its Aurora demonstration on schedule (targeting 2027), NNE's designs have to materially differentiate or they become scientific curiosities. A second risk: the 18% share dilution over the past 12 months — micro-reactor companies fundraise continuously, and the float can double before revenue materializes.
3. Lightbridge (LTBR) — Score: 36.0 | Grade: HIGH RISK
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | 0% | 0 |
| Gross Margin | N/A | 0 |
| Cash Runway | >36 months | 100 |
| Debt/Equity | Net cash | 100 |
| P/S Ratio | N/A (no revenue) | 50 |
| Rule of 40 | N/A | 0 |
| Insider Ownership | 3.5% | 28 |
| 12m Dilution | +11.0% | 35 |
What drives the score: Lightbridge designs metallic-alloy nuclear fuel rods that claim higher power density and longer cycle lengths than conventional uranium oxide fuel. The technical thesis is credible — extensive validation work has been done at Idaho National Laboratory and Oak Ridge — and the addressable market includes both existing LWR fleet upgrades and SMR fuel. What it lacks is commercial adoption: Lightbridge has been public since 2006 and still has no commercial revenue. Runway is solid (>36 months) because ongoing dilution has kept the cash balance healthy; the dilution-to-reach-revenue trade is the whole thesis.
Key risk: The specific failure mode is simple: the utility industry is deeply conservative on fuel, and every year without a commercial fuel-loading milestone is one year closer to thesis failure. Insider ownership at 3.5% is the weakest signal here — management does not have meaningful skin-in-the-game relative to the micro-reactor peers. This is a long-duration, high-conviction-only idea.
What these stocks have in common
Looking across the three picks, three patterns emerge:
-
Runway is the only metric that matters. All three score 100/100 on runway (>36 months). Revenue, margin, and Rule of 40 are near-zero or undefined for two of three. For pre-commercial nuclear, survival to milestone is the entire investment thesis — the scoring model is right to weight runway above everything else here.
-
Dilution is the silent killer. ASPI has diluted 30% in 12 months, NNE 18%, LTBR 11%. Aggregated, the entire pre-commercial nuclear sub-sector funds itself through equity issuance, and investors should assume the share count grows another 40-80% before any meaningful revenue arrives.
-
Insider ownership varies wildly. NNE's 22% insider ownership is unusually high — a positive signal that founders are exposed to the outcome they're promising. LTBR's 3.5% is the opposite signal.
What's not on this list — and why
Four prominent nuclear names investors typically search for at the small-cap level:
- Oklo (OKLO) — $14B+ market cap. Already a large-cap. The Aurora microreactor is furthest along in NRC engagement, but the stock price reflects that fully; upside requires successful demonstration by 2027, and any slippage is priced to fall sharply.
- NuScale Power (SMR) — $6B+ market cap. First NRC-approved SMR design but also the company that watched its flagship Carbon Free Power Project cancel in 2023 after costs escalated; the bull case is a Romania deployment plus DOE funding, the bear case is a reminder that first-mover in nuclear doesn't guarantee project-level economics.
- BWX Technologies (BWXT) — $11B market cap. Not a small-cap story; included here because retail investors often group it with SMR pure-plays. BWXT's Advanced Technologies segment is real SMR exposure (microreactors for DOD, NASA), but the main business remains naval reactor components — different thesis, different valuation.
- Centrus Energy (LEU) — $6B market cap. The only US-based commercial HALEU producer, operator of the Piketon cascade. A cleaner pure-play than anything on our list, but graduated out of small-cap range in late 2024.
This is the recurring pattern of small-cap sector analysis in 2026: the winners scale out, the remainders are a mix of genuine sub-scale survivors and names that never made it. Treat small-cap nuclear accordingly. If you want clean pure-play SMR exposure, the allocation belongs in the mid-caps above. If you want asymmetric small-cap upside, ASPI is the only name here where the business is actually generating revenue.
How to use this data
These scores measure fundamental quality for pre-commercial companies where the main question is survivability. A high score means the balance sheet and runway give the business a real chance to reach a value-creating milestone. It does not mean the stock will outperform — especially in a sector this binary.
For each name on this list, before deciding anything:
- Read the most recent 10-Q to verify cash burn hasn't accelerated since our last score update
- For ASPI specifically, track the DOE HALEU Availability Program contract awards — the next round decides a lot
- For NNE, watch for an NRC pre-application filing; without one, 2027 is not a realistic demonstration target
- Understand that for small-cap nuclear, position sizing should be 1-3% of a diversified portfolio — not 10%
SmallCapScanner scores are calculated algorithmically based on 8 fundamental factors. They measure financial health, not future performance. See /how-it-works for the full methodology.
Track these stocks and 2,200+ others on our screener. Set alerts to know when a score crosses your threshold, or compare two tickers directly on /compare.